|
US4534899A
(en)
|
1981-07-20 |
1985-08-13 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
AU5661386A
(en)
|
1985-03-15 |
1986-10-13 |
Stirchak, E. |
Stereoregular polynucleotide-binding polymers
|
|
US5506337A
(en)
|
1985-03-15 |
1996-04-09 |
Antivirals Inc. |
Morpholino-subunit combinatorial library and method
|
|
US5166315A
(en)
|
1989-12-20 |
1992-11-24 |
Anti-Gene Development Group |
Sequence-specific binding polymers for duplex nucleic acids
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5185444A
(en)
|
1985-03-15 |
1993-02-09 |
Anti-Gene Deveopment Group |
Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
|
|
US5521063A
(en)
|
1985-03-15 |
1996-05-28 |
Antivirals Inc. |
Polynucleotide reagent containing chiral subunits and methods of use
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US5354844A
(en)
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
|
US5108921A
(en)
|
1989-04-03 |
1992-04-28 |
Purdue Research Foundation |
Method for enhanced transmembrane transport of exogenous molecules
|
|
US5227170A
(en)
|
1989-06-22 |
1993-07-13 |
Vestar, Inc. |
Encapsulation process
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5356633A
(en)
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
|
US5527528A
(en)
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5469854A
(en)
|
1989-12-22 |
1995-11-28 |
Imarx Pharmaceutical Corp. |
Methods of preparing gas-filled liposomes
|
|
US5580575A
(en)
|
1989-12-22 |
1996-12-03 |
Imarx Pharmaceutical Corp. |
Therapeutic drug delivery systems
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
JP3220180B2
(ja)
|
1991-05-23 |
2001-10-22 |
三菱化学株式会社 |
薬剤含有タンパク質結合リポソーム
|
|
US5719262A
(en)
|
1993-11-22 |
1998-02-17 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having amino acid side chains
|
|
US5539082A
(en)
|
1993-04-26 |
1996-07-23 |
Nielsen; Peter E. |
Peptide nucleic acids
|
|
US5714331A
(en)
|
1991-05-24 |
1998-02-03 |
Buchardt, Deceased; Ole |
Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
|
|
WO1993001286A2
(en)
|
1991-06-28 |
1993-01-21 |
Massachusetts Institute Of Technology |
Localized oligonucleotide therapy
|
|
US5521291A
(en)
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
|
NZ244306A
(en)
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
|
FR2692265B1
(fr)
|
1992-05-25 |
1996-11-08 |
Centre Nat Rech Scient |
Composes biologiquement actifs de type phosphotriesters.
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
EP1498427B1
(en)
|
1992-08-21 |
2009-12-16 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
US5583020A
(en)
|
1992-11-24 |
1996-12-10 |
Ribozyme Pharmaceuticals, Inc. |
Permeability enhancers for negatively charged polynucleotides
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
US5395619A
(en)
|
1993-03-03 |
1995-03-07 |
Liposome Technology, Inc. |
Lipid-polymer conjugates and liposomes
|
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
ES2201076T3
(es)
|
1993-03-19 |
2004-03-16 |
The Johns Hopkins University School Of Medicine |
Factor-8 de diferenciacion del crecimiento.
|
|
US5462854A
(en)
|
1993-04-19 |
1995-10-31 |
Beckman Instruments, Inc. |
Inverse linkage oligonucleotides for chemical and enzymatic processes
|
|
DK0698097T3
(da)
|
1993-04-29 |
2001-10-08 |
Unilever Nv |
Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5543158A
(en)
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US5543152A
(en)
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5512295A
(en)
|
1994-11-10 |
1996-04-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Synthetic liposomes for enhanced uptake and delivery
|
|
US5707618A
(en)
|
1995-03-24 |
1998-01-13 |
Genzyme Corporation |
Adenovirus vectors for gene therapy
|
|
DK2111876T3
(da)
|
1995-12-18 |
2011-12-12 |
Angiodevice Internat Gmbh |
Tværbundne polymerpræparater og fremgangsmåder til anvendelse deraf
|
|
US6245747B1
(en)
|
1996-03-12 |
2001-06-12 |
The Board Of Regents Of The University Of Nebraska |
Targeted site specific antisense oligodeoxynucleotide delivery method
|
|
WO1999002667A1
(en)
*
|
1997-07-14 |
1999-01-21 |
University Of Liege |
Mutations in the myostation gene cause double-muscling in mammals
|
|
US7572582B2
(en)
|
1997-09-12 |
2009-08-11 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US6794499B2
(en)
|
1997-09-12 |
2004-09-21 |
Exiqon A/S |
Oligonucleotide analogues
|
|
US7084125B2
(en)
|
1999-03-18 |
2006-08-01 |
Exiqon A/S |
Xylo-LNA analogues
|
|
AU776362B2
(en)
|
1999-05-04 |
2004-09-09 |
Roche Innovation Center Copenhagen A/S |
L-ribo-LNA analogues
|
|
US6284882B1
(en)
|
1999-06-10 |
2001-09-04 |
Abbott Laboratories |
Myostatin gene promoter and inhibition of activation thereof
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
EP1191097A1
(en)
|
2000-09-21 |
2002-03-27 |
Leids Universitair Medisch Centrum |
Induction of exon skipping in eukaryotic cells
|
|
US20050124566A1
(en)
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
|
CA2459347C
(en)
|
2001-09-04 |
2012-10-09 |
Exiqon A/S |
Locked nucleic acid (lna) compositions and uses thereof
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
KR100464261B1
(ko)
|
2002-01-24 |
2005-01-03 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
KR20030084444A
(ko)
|
2002-04-26 |
2003-11-01 |
주식회사 파나진 |
Ｐｎａ 올리고머를 합성하기 위한 신규한 단량체 및 그의제조방법
|
|
US7569575B2
(en)
|
2002-05-08 |
2009-08-04 |
Santaris Pharma A/S |
Synthesis of locked nucleic acid derivatives
|
|
WO2004044140A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceticals, Inc. |
2’-substituted oligomeric compounds and compositions for use in gene modulations
|
|
AU2003225410A1
(en)
|
2003-03-21 |
2004-10-11 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
|
|
ES2351976T3
(es)
*
|
2003-04-29 |
2011-02-14 |
Avi Biopharma, Inc. |
Composiciones para mejorar el transporte y la eficacia antisentido de análogos de ácidos nucleicos en células.
|
|
US7211668B2
(en)
|
2003-07-28 |
2007-05-01 |
Panagene, Inc. |
PNA monomer and precursor
|
|
SI2206781T1
(sl)
|
2004-06-28 |
2016-05-31 |
The University Of Western Australia |
Protismiselni oligonukleotidi za induciranje preskakovanja eksona in postopki njihove uporabe
|
|
US7838657B2
(en)
|
2004-12-03 |
2010-11-23 |
University Of Massachusetts |
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
ES2852549T3
(es)
*
|
2005-02-09 |
2021-09-13 |
Sarepta Therapeutics Inc |
Composición antisentido para tratamiento de la atrofia muscular
|
|
CA2605512A1
(en)
|
2005-04-22 |
2006-10-26 |
Academisch Ziekenhuis Leiden |
Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
|
|
BRPI0610248A2
(pt)
|
2005-04-25 |
2010-06-08 |
Pfizer |
anticorpos contra miostatina, composição farmacêutica compreendendo os mesmos, linhas celulares que os produzem , moléculas de ácido nucleico codificantes dos mesmos bem como seus usos
|
|
CA2538208A1
(en)
|
2005-05-04 |
2006-11-04 |
Universite Laval |
Modulation of myostatin and use thereof in cell transplantation-based treatment of muscle disease
|
|
DE202005008426U1
(de)
|
2005-05-31 |
2005-09-15 |
Ricon Sieb Und Foerdertechnik |
Fördervorrichtung mit Fördertuch
|
|
US8361977B2
(en)
|
2005-06-23 |
2013-01-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of SMN2 splicing
|
|
WO2007003216A1
(en)
|
2005-07-06 |
2007-01-11 |
Universidad Autónoma de Madrid |
Anti-ccr7 receptor antibodies for the treatment of cancer
|
|
ES2657400T3
(es)
|
2006-05-10 |
2018-03-05 |
Sarepta Therapeutics, Inc. |
Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
|
|
EP1857548A1
(en)
|
2006-05-19 |
2007-11-21 |
Academisch Ziekenhuis Leiden |
Means and method for inducing exon-skipping
|
|
US8097596B2
(en)
*
|
2006-06-30 |
2012-01-17 |
Lakewood-Amedex, Inc. |
Compositions and methods for the treatment of muscle wasting
|
|
WO2008088895A2
(en)
|
2007-01-18 |
2008-07-24 |
University Of Missouri-Columbia |
Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
|
|
TW201940502A
(zh)
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
US20100016215A1
(en)
|
2007-06-29 |
2010-01-21 |
Avi Biopharma, Inc. |
Compound and method for treating myotonic dystrophy
|
|
AU2008271050B2
(en)
*
|
2007-06-29 |
2014-11-06 |
Sarepta Therapeutics, Inc. |
Tissue specific peptide conjugates and methods
|
|
WO2009008725A2
(en)
|
2007-07-12 |
2009-01-15 |
Prosensa Technologies B.V. |
Molecules for targeting compounds to various selected organs, tissues or tumor cells
|
|
US7935816B2
(en)
|
2007-10-25 |
2011-05-03 |
Gene Tools, Llc |
Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
|
|
DK2203173T3
(en)
|
2007-10-26 |
2016-02-29 |
Academisch Ziekenhuis Leiden |
Materials and methods for prevention of muscle diseases
|
|
US8076476B2
(en)
|
2007-11-15 |
2011-12-13 |
Avi Biopharma, Inc. |
Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
|
|
CA2884340C
(en)
|
2007-11-15 |
2017-07-25 |
Sarepta Therapeutics, Inc. |
Method of synthesis of morpholino oligomers
|
|
CA2711302C
(en)
|
2008-01-04 |
2016-11-08 |
Cue Acoustics, Inc. |
Audio device with integrated switching power supply
|
|
EP2119783A1
(en)
|
2008-05-14 |
2009-11-18 |
Prosensa Technologies B.V. |
Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
|
|
US8236557B2
(en)
|
2008-05-28 |
2012-08-07 |
University Of Missouri-Columbia |
Hybrid-AAV vectors to deliver large gene expression cassette
|
|
LT3750552T
(lt)
|
2008-08-14 |
2023-06-26 |
Acceleron Pharma Inc. |
Gdf gaudyklės
|
|
US8084601B2
(en)
|
2008-09-11 |
2011-12-27 |
Royal Holloway And Bedford New College Royal Holloway, University Of London |
Oligomers
|
|
EP2762567B1
(en)
|
2008-10-24 |
2016-07-13 |
Sarepta Therapeutics, Inc. |
Multiple exon skipping compositions for DMD
|
|
CN102625840A
(zh)
|
2009-04-10 |
2012-08-01 |
肌肉学研究协会 |
用于治疗疾病的三环dna反义寡核苷酸、组合物和方法
|
|
WO2010120820A1
(en)
|
2009-04-13 |
2010-10-21 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of smn2 splicing
|
|
ES2593836T3
(es)
|
2009-04-24 |
2016-12-13 |
Biomarin Technologies B.V. |
Oligonucleótido que comprende una inosina para tratar la DMD
|
|
EA027071B1
(ru)
|
2009-04-27 |
2017-06-30 |
Новартис Аг |
АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
|
|
WO2010129406A2
(en)
*
|
2009-05-04 |
2010-11-11 |
The Johns Hopkins University |
Methods of promoting muscle growth
|
|
PT3449926T
(pt)
|
2009-06-17 |
2019-11-12 |
Cold Spring Harbor Laboratory |
Composições e métodos de modulação de excisões de smn2 em um sujeito
|
|
SMT201800579T1
(it)
|
2009-11-12 |
2019-01-11 |
Univ Western Australia |
Molecole antisenso e metodi per trattare patologie
|
|
US8802642B2
(en)
|
2010-04-28 |
2014-08-12 |
Iowa State University Research Foundation, Inc. |
Spinal muscular atrophy treatment via targeting SMN2 catalytic core
|
|
JP2013530154A
(ja)
|
2010-05-28 |
2013-07-25 |
サレプタ セラピューティクス， インコーポレイテッド |
修飾されたサブユニット間結合および／または末端基を有するオリゴヌクレオチドアナログ
|
|
TWI541024B
(zh)
|
2010-09-01 |
2016-07-11 |
日本新藥股份有限公司 |
反義核酸
|
|
PL2623507T3
(pl)
|
2010-09-30 |
2017-03-31 |
Nippon Shinyaku Co., Ltd. |
Pochodna kwasu morfolinonukleinowego
|
|
EP2672977A1
(en)
|
2011-02-08 |
2013-12-18 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Antisense oligonucleotides
|
|
WO2012150960A1
(en)
|
2011-05-05 |
2012-11-08 |
Avi Biopharma, Inc. |
Peptide oligonucleotide conjugates
|
|
US20130085139A1
(en)
*
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
ES2535654T3
(es)
|
2011-10-13 |
2015-05-13 |
Association Institut De Myologie |
ADN triciclo-fosforotioato
|
|
BR112014011875B1
(pt)
|
2011-11-18 |
2022-01-04 |
Sarepta Therapeutics, Inc |
Oligonucleotídeos funcionalmente modificados e subunidades dos mesmos
|
|
US9434928B2
(en)
|
2011-11-23 |
2016-09-06 |
Nationwide Children's Hospital, Inc. |
Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
|
|
CN108611349A
(zh)
|
2011-12-28 |
2018-10-02 |
日本新药株式会社 |
反义核酸
|
|
ES2907250T3
(es)
|
2012-01-27 |
2022-04-22 |
Biomarin Tech Bv |
Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker
|
|
AU2013285698A1
(en)
*
|
2012-07-03 |
2015-02-19 |
Biomarin Technologies B.V. |
Oligonucleotide for the treatment of muscular dystrophy patients
|
|
KR20150099804A
(ko)
|
2012-12-20 |
2015-09-01 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
|
|
AU2014236140B2
(en)
|
2013-03-14 |
2019-10-03 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
NZ732507A
(en)
*
|
2013-03-15 |
2018-08-31 |
Sarepta Therapeutics Inc |
Improved compositions for treating muscular dystrophy
|
|
WO2014172448A2
(en)
|
2013-04-17 |
2014-10-23 |
Anaptysbio, Inc. |
Antibodies directed against activin receptor type ii (actrii)
|
|
IL282239B2
(en)
*
|
2013-09-05 |
2023-10-01 |
Sarepta Therapeutics Inc |
Antisense-induced exon2 inclusion in acid alpha-glucosidase
|
|
US10867398B2
(en)
|
2017-11-21 |
2020-12-15 |
Reliance Core Consulting LLC |
Methods, systems, apparatuses and devices for facilitating motion analysis in an environment
|